Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553112 | 0.84 | POLB (0.44) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL3439980 | 0.82 | POLB (0.73) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL12952781 | 0.82 | SIRT6 (0.71) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL6151230 | 0.82 | SIRT6 (0.81) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL15271381 | 0.82 | SIRT6 (0.81) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL8310107 | 0.82 | ALDH1A1 (0.57) | POLBMAPTMEN1KMT2AATM | |
| SCHEMBL1645682 | 0.82 | HSD11B1 (0.60) | POLBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7832804 | 0.81 | HDAC1 (0.57) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL31683275 | 0.79 | SIRT6 (0.62) | POLBSIRT6MAPTMEN1KMT2A | |
| SCHEMBL7987707 | 0.78 | MAPT (0.70) | POLBSIRT6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3728234-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111511732-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-2097413-B1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-4788196-A | Phenyl piperazine anti-arrhythmia agents | PFIZER INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0244115-A2 | Phenyl-piperazine anti-arrhythmia agents | Pfizer Limited (GB) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | POLB 824/4885SIRT6 3850/4885MAPT 16/4885 |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | POLB 4825/4885SIRT6 1636/4885MAPT 1771/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | POLB 836/4885SIRT6 3927/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.